Sarcopenia Treatment Market Report

Sarcopenia is defined as age-related loss of muscle mass and is a key physiological component of frailty. Moreover, sarcopenia is associated with increased risk for several adverse health outcomes such as frailty, disability, falls and mortality. The major mechanisms leading to sarcopenia include age-related decline in α-motor neurons, IGF-1, and DHEA-S and increase in catabolic cytokines (IL-6). The condition is also characterized by a significant decrease in skeletal muscle protein synthesis and increase in protein breakdown. Age related sarcopenia is considered primary, while sarcopenia is considered secondary when factors other than ageing such as disease and nutrition are evident.

Factors such as rising prevalence of sarcopenia with increasing geriatric population, increasing research and development activities for development of novel therapies and increasing initiatives by government and private organizations are anticipated to boost the growth of the market. However, low awareness and absence of curative therapy is expected to hinder the growth of sarcopenia market.

Among the analyzed regions, currently, North America is the highest revenue contributor, and is expected to maintain the lead during the forecast period, followed by Europe, Asia Pacific, Latin America, Middle East and Africa.